Use of Bone Morphogenetic Protein Among Patients Undergoing Fusion for Degenerative Diagnoses in the United States, 2002–2012

BACKGROUND CONTEXT: Use of Bone Morphogenetic Protein (BMP) as an adjunct to spinal fusion surgery proliferated following Food and Drug Administration (FDA) approval in 2002. Major safety concerns emerged in 2008. PURPOSE: To examine whether published concerns about the safety of BMP altered clinica...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Spine J
Asıl Yazarlar: Martin, Brook I., Lurie, Jon D., Deyo, Richard A., Tosteson, Anna N.A., Farrokhi, Farrokh Reza, Mirza, Sohail K.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2014
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4375057/
https://ncbi.nlm.nih.gov/pubmed/25523380
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.spinee.2014.12.010
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller